Denmark pharmaceutical giant Novo Nordisk announced on Tuesday that it is suing its main competitor, the US-based Eli Lilly for “false and misleading” advertisements.
Novo Nordisk says that its rival is using “intentionally selected outdated studies” that compare higher doses of its popular GLP-1 agonist drugs Wegovy and Ozempic to lower doses of Eli Lilly’s Mounjaro and Zepbound.
The American firm’s ads are “deceptively (presented) those results as proof of broad, product-level superiority while burying or omitting critical clinical context,” the Danish group said.
“As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions,” the company’s general counsel John F. Kuckelman said.
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
At the heart of the suit is a Eli Lilly campaign that Novo Nordisk claims “aired during recent, widely viewed global sporting broadcasts and on TikTok and Facebook, causing widespread confusion.”
The lawsuit has been launched in a US district court in New Jersey, specifically alleging breaches of fair competition laws and federal false advertising statutes.
What is a GLP-1?
These medications mimic the body’s natural GLP-1 hormone, which is produced by your body after you eat, using it to control apetite.
Both Novo Nordisk and Eli Lilly have developed seperate synthetic GLP-1 molecules.
They can be used to treat type 2 diabetes as well as a weight loss drug, the popularity of the latter creating massive windfalls for both companies.
Edited by: Jenipher Camino Gonzalez
Don’t let the algorithm hide the news. If you rely on our team for trusted reporting, please take a moment to select us as your Preferred Source on Google by clicking here and hitting the “star” or “preferred” button, so you’ll always see our verified news first.
About The Author
